# Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer

Source: https://onco.cc/trials/nct07139470/  
OnCo record `nct07139470` (Trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)"; commercial use needs a licence.

## TL;DR

A phase 1/2 trial of sacituzumab tirumotecan and anlotinib in triple-negative breast cancer, run by Tianjin Medical University Cancer Institute and Hospital, not yet recruiting.

## Summary

Sacituzumab Tirumotecan Plus Anlotinib for Metastatic Triple Negative Breast Cancer is a phase 1/2, interventional study registered as NCT07139470 by Tianjin Medical University Cancer Institute and Hospital, with a registry enrolment figure of 59 participants, started 2025-08-15 and due to reach its primary completion in 2027-04-15. Interventions recorded: Sacituzumab Tirumotecan + anlotinib. Conditions listed: Triple Negative Breast Cancer. Triple-negative eligibility wording from the registry: "* Histologically and/or cytologically confirmed triple-negative breast cancer (TNBC) based on the most recent biopsy or pathological specimen, including:". Sites: China. No results are recorded here; the registry entry is the source.

## Fields

- Kind: Trial
- Status: planned
- Last checked: 2026-09-24
- Tags: ctgov-ingest; tnbc-deep-dive
- Registry id: NCT07139470
- Phase: 1/2
- Setting: An Open-label, Single-arm, Multicenter Phase I/II Study of Sacituzumab Tirumotecan (Sac-TMT) Plus Anlotinib in Previously Treated Metastatic Triple Negative Breast Cancer (mTNBC).
- Sponsor: Tianjin Medical University Cancer Institute and Hospital
- Enrolled: 59

## Sources

- ClinicalTrials.gov NCT07139470: https://clinicaltrials.gov/study/NCT07139470

## Connected records

- cancers: [Metastatic triple-negative breast cancer](https://onco.cc/cancers/tnbc-metastatic/)
- technologies: [Antibody-drug conjugate (ADC)](https://onco.cc/technologies/adc/)
- drugs: [Anlotinib](https://onco.cc/drugs/anlotinib/), [Sacituzumab tirumotecan](https://onco.cc/drugs/sacituzumab-tirumotecan/)
- terms: [Triple-negative breast cancer trials open today (registry snapshot and UK sites)](https://onco.cc/terms/tnbc-trials-open-today/)

---
JSON: https://onco.cc/api/v1/entities/nct07139470.json